Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.70084 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Awais Sheikh und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, University College London, London, UK. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition primarily affecting older adults, who are at increased risk of morbidity and mortality. In HELIOS-B, vutrisiran reduced all-cause mortality and recurrent cardiovascular events versus placebo in patients with ATTR-CM. This prespecified analysis evaluated efficacy and safety outcomes by age category (<75, 75 to <80, and ≥80 years) and across age as a continuous measure. Methods and results HELIOS-B randomized patients with ATTR-CM in a 1:1 ratio to vutrisiran 25 mg or placebo every 12 weeks for up to 36 months. Eligible patients were aged 18–85 years. We assessed the primary composite of all-cause mortality and recurrent cardiovascular events, changes in 6-min walk test (6MWT) and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS), and safety outcomes across age groups. Among 654 patients (aged 45–85 years; mean 75.3 ± 6.7), 257 (39.3%) were <75, 201 (30.7%) 75 to <80, and 196 (30.0%) ≥80 years. Vutrisiran reduced the risk of the primary composite outcome in all age categories (pinteraction = 0.56) and across the age spectrum as a continuous function (pinteraction = 0.50). Consistent benefits were seen for individual outcome components, with no significant interaction between treatment and age. Functional capacity and quality of life were preserved across age groups (pinteraction = 0.35 and = 1.00 for KCCQ-OSS and 6MWT, respectively). Safety was comparable across groups, with no increase in adverse events in older patients.
Conclusions
Vutrisiran reduced all-cause mortality and cardiovascular events and maintained function and quality of life in patients with ATTR-CM across the age spectrum, including those ≥80 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Amyloidosis Centre, University College London, London, UK.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
- Tuscan Regional Amyloid Center, Careggi University Hospital, Florence, Italy.
- Alnylam Pharmaceuticals, Cambridge, MA, USA.
Zitieren
APA
Sheikh, A., Miao, Z. M., Claggett, B., Garcia-Pavia, P., Cappelli, F., Aldinc, E., Gillmore, J., Solomon, S. D., & Fontana, M. (2025). Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.70084
Vancouver
Sheikh A, Miao ZM, Claggett B, Garcia-Pavia P, Cappelli F, Aldinc E, et al. Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.70084
BibTeX
@article{Sheikh2025,
author = {Sheikh, Awais and Miao, Zi Michael and Claggett, Brian and Garcia-Pavia, Pablo and Cappelli, Francesco and Aldinc, Emre and Gillmore, Julian and Solomon, Scott D and Fontana, Marianna},
title = {Efficacy and Safety of Vutrisiran in Transthyretin Amyloid Cardiomyopathy Across the Age Spectrum: The HELIOS-B Trial},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.70084}
}
EUVIMED